A citation-based method for searching scientific literature

Asako Azuma, Mitsuhiro Tozaki, Kensuke Ito, Eisuke Fukuma, Tomoko Tanaka, Toshihiro O'uchi. Radiat Med 2008
Times Cited: 11







List of co-cited articles
32 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
N Avril, M Menzel, J Dose, M Schelling, W Weber, F Jänicke, W Nathrath, M Schwaiger. J Nucl Med 2001
302
45

Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.
N Avril, C A Rosé, M Schelling, J Dose, W Kuhn, S Bense, W Weber, S Ziegler, H Graeff, M Schwaiger. J Clin Oncol 2000
353
36

Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake.
R S Brown, J Y Leung, S J Fisher, K A Frey, S P Ethier, R L Wahl. J Nucl Med 1996
114
27


Role of FDG-PET/CT in prediction of underestimation of invasive breast cancer in cases of ductal carcinoma in situ diagnosed at needle biopsy.
Hideo Shigematsu, Takayuki Kadoya, Norio Masumoto, Kazuo Matsuura, Akiko Emi, Keiko Kajitani, Ai Amioka, Morihito Okada. Clin Breast Cancer 2014
10
30

Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor.
Songji Zhao, Yuji Kuge, Takafumi Mochizuki, Toshiyuki Takahashi, Kunihiro Nakada, Masayuki Sato, Toshiki Takei, Nagara Tamaki. J Nucl Med 2005
143
18

FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors.
T Higashi, N Tamaki, T Torizuka, Y Nakamoto, H Sakahara, T Kimura, T Honda, T Inokuma, S Katsushima, G Ohshio,[...]. J Nucl Med 1998
132
18

[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?
Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, Guy Bormans, Jan Balzarini, Gregor Verhoef, Luc Mortelmans, Peter Vandenberghe, Christine De Wolf-Peeters. Eur J Nucl Med Mol Imaging 2003
154
18

Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding.
Y E Erdi, O Mawlawi, S M Larson, M Imbriaco, H Yeung, R Finn, J L Humm. Cancer 1997
337
18

A gradient-based method for segmenting FDG-PET images: methodology and validation.
Xavier Geets, John A Lee, Anne Bol, Max Lonneux, Vincent Grégoire. Eur J Nucl Med Mol Imaging 2007
268
18

How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study.
Barbara M Fischer, Minna W B Olsen, Carsten D Ley, Thomas L Klausen, Jann Mortensen, Liselotte Højgaard, Paul E G Kristjansen. Eur J Nucl Med Mol Imaging 2006
43
18

Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer.
Ursula Nestle, Stephanie Kremp, Andrea Schaefer-Schuler, Christiane Sebastian-Welsch, Dirk Hellwig, Christian Rübe, Carl-Martin Kirsch. J Nucl Med 2005
445
18

Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms.
Jean-François Daisne, Mérence Sibomana, Anne Bol, Thomas Doumont, Max Lonneux, Vincent Grégoire. Radiother Oncol 2003
271
18

A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data.
Andrea Schaefer, Stephanie Kremp, Dirk Hellwig, Christian Rübe, Carl-Martin Kirsch, Ursula Nestle. Eur J Nucl Med Mol Imaging 2008
105
18

Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Masahiro Ohara, Hideo Shigematsu, Yasuhiro Tsutani, Akiko Emi, Norio Masumoto, Shinji Ozaki, Takayuki Kadoya, Morihito Okada. Breast 2013
35
18

Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer.
Meagan E Brennan, Robin M Turner, Stefano Ciatto, M Luke Marinovich, James R French, Petra Macaskill, Nehmat Houssami. Radiology 2011
224
18

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Karla Kerlikowske, Annette M Molinaro, Mona L Gauthier, Hal K Berman, Fred Waldman, James Bennington, Henry Sanchez, Cynthia Jimenez, Kim Stewart, Karen Chew,[...]. J Natl Cancer Inst 2010
231
18

Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications.
Mathieu Hatt, Catherine Cheze le Rest, Patrice Descourt, André Dekker, Dirk De Ruysscher, Michel Oellers, Philippe Lambin, Olivier Pradier, Dimitris Visvikis. Int J Radiat Oncol Biol Phys 2010
128
18

Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer.
A Gil-Rendo, F Martínez-Regueira, G Zornoza, M J García-Velloso, C Beorlegui, N Rodriguez-Spiteri. Br J Surg 2009
117
18

Ductal carcinoma in-situ of the breast detected by [F-18] fluorodeoxyglucose positron emission tomography.
Tetsuhiro Owaki, Yuko Kijima, Heiji Yoshinaka, Yoshikazu Uenosono, Takako Yoshioka, Shoji Natsugoe, Takashi Aikou. Breast Cancer 2006
6
33

Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.
Ayse Mavi, Muammer Urhan, Jian Q Yu, Hongming Zhuang, Mohamed Houseni, Tevfik F Cermik, Dhurairaj Thiruvenkatasamy, Brian Czerniecki, Mitchell Schnall, Abass Alavi. J Nucl Med 2006
122
18

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.
E de Azambuja, F Cardoso, G de Castro, M Colozza, M S Mano, V Durbecq, C Sotiriou, D Larsimont, M J Piccart-Gebhart, M Paesmans. Br J Cancer 2007
592
18

Quantitation in positron emission computed tomography: 1. Effect of object size.
E J Hoffman, S C Huang, M E Phelps. J Comput Assist Tomogr 1979
969
18

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
D C Allred, J M Harvey, M Berardo, G M Clark. Mod Pathol 1998
18

Positron emission tomography in breast cancer: a clinicopathological correlation of results.
A Y Rostom, J Powe, A Kandil, A Ezzat, S Bakheet, F el-Khwsky, G el-Hussainy, R Sorbris, O Sjoklint. Br J Radiol 1999
55
18

FDG-PET and beyond: molecular breast cancer imaging.
Andrew Quon, Sanjiv S Gambhir. J Clin Oncol 2005
100
18

Defining the role of PET-CT in staging early breast cancer.
Ashley M Groves, Manu Shastry, Simona Ben-Haim, Irfan Kayani, Anmol Malhotra, Timothy Davidson, Tina Kelleher, Diane Whittaker, Marie Meagher, Brian Holloway,[...]. Oncologist 2012
32
18

Occasional FDG PET recognition of in situ breast cancer.
B Vincenzi, A Calvieri, D Santini, V Altomare, G Tonini. Ann Oncol 2007
2
100


Clinicopathological Features of Cases with Primary Breast Cancer not Identified by 18F-FDG-PET.
Takaaki Fujii, Reina Yajima, Miki Tsuboi, Toru Higuchi, Sayaka Obayashi, Hideaki Tokiniwa, Rin Nagaoka, Daisuke Takata, Jun Horiguchi, Hiroyuki Kuwano. Anticancer Res 2016
5
40


Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study.
Tomoyuki Fujioka, Kazunori Kubota, Akira Toriihara, Youichi Machida, Kaori Okazawa, Tsuyoshi Nakagawa, Yukihisa Saida, Ukihide Tateishi. World J Radiol 2016
9
22


2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.
Paula Wells, Eric Aboagye, Roger N Gunn, Safiye Osman, Alan V Boddy, Gordon A Taylor, Imran Rafi, Andrew N Hughes, A Hilary Calvert, Pat M Price,[...]. J Natl Cancer Inst 2003
45
9

Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Laura Kenny, R Charles Coombes, David M Vigushin, Adil Al-Nahhas, Sami Shousha, Eric O Aboagye. Eur J Nucl Med Mol Imaging 2007
208
9

Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography.
Laura M Kenny, Kaiyumars B Contractor, Justin Stebbing, Adil Al-Nahhas, Carlo Palmieri, Sami Shousha, R Charles Coombes, Eric O Aboagye. Clin Cancer Res 2009
44
9

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
P Therasse, S G Arbuck, E A Eisenhauer, J Wanders, R S Kaplan, L Rubinstein, J Verweij, M Van Glabbeke, A T van Oosterom, M C Christian,[...]. J Natl Cancer Inst 2000
9

Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma.
Hirofumi Koga, Yoshio Matsuo, Masayuki Sasaki, Makoto Nakagawa, Koichiro Kaneko, Kazutaka Hayashi, Yasuo Kuwabara, Hiroshi Honda. Ann Nucl Med 2003
20
9

Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer.
Yuka Yamamoto, Yoshihiro Nishiyama, Shinya Ishikawa, Jun Nakano, Sung Soo Chang, Shuji Bandoh, Nobuhiro Kanaji, Reiji Haba, Yoshio Kushida, Motoomi Ohkawa. Eur J Nucl Med Mol Imaging 2007
116
9

Imaging of cell proliferation: status and prospects.
James R Bading, Anthony F Shields. J Nucl Med 2008
227
9

In vivo detection of apoptosis.
Francis G Blankenberg. J Nucl Med 2008
170
9

Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
Hubert Vesselle, Alexander Salskov, Eric Turcotte, Linda Wiens, Rodney Schmidt, C Diana Jordan, Eric Vallières, Douglas E Wood. J Thorac Oncol 2008
114
9

Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine.
U Haberkorn, I Morr, F Oberdorfer, M E Bellemann, J Blatter, A Altmann, B Kahn, G van Kaick. J Nucl Med 1994
48
9

Bone imaging in metastatic breast cancer.
Tsuyoshi Hamaoka, John E Madewell, Donald A Podoloff, Gabriel N Hortobagyi, Naoto T Ueno. J Clin Oncol 2004
353
9

Update on endocrine therapy for breast cancer.
A U Buzdar, G Hortobagyi. Clin Cancer Res 1998
71
9

Lung tumors evaluated with FDG-PET and dynamic CT: the relationship between vascular density and glucose metabolism.
Ukihide Tateishi, Hiroshi Nishihara, Eriko Tsukamoto, Toshiaki Morikawa, Nagara Tamaki, Kazuo Miyasaka. J Comput Assist Tomogr 2002
80
9

Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study.
Dirk De Ruysscher, Ans Houben, Hugo J W L Aerts, Cary Dehing, Rinus Wanders, Michel Ollers, Anne-Marie C Dingemans, Monique Hochstenbag, Liesbeth Boersma, Jacques Borger,[...]. Radiother Oncol 2009
56
9

Monitoring predominantly cytostatic treatment response with 18F-FDG PET.
Kaiyumars B Contractor, Eric O Aboagye. J Nucl Med 2009
67
9


Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
Chi Tarn, Yuliya V Skorobogatko, Takahiro Taguchi, Burton Eisenberg, Margaret von Mehren, Andrew K Godwin. Cancer Res 2006
63
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.